Advancing Vaccine Equity Through Understanding Vaccine Hesitancy, Barriers, and Trust
NCT ID: NCT05537714
Last Updated: 2023-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2023-08-06
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Vaccine Confidence and Uptake of Potential COVID-19 Vaccines
NCT04731870
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
NCT05796505
Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination
NCT05977192
COVID-19 Testing and Vaccination Among Spanish Speakers
NCT05302908
Community Care Intervention to Decrease COVID-19 Vaccination Inequities
NCT06156254
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective 2: To assess vaccine messaging from trusted individuals (e.g., clergy/church leaders, community health workers, and community leaders) who serve medically underserved and vulnerable populations living in the rural south.
Objective 3: To identify best vaccine confidence and uptake strategies to improve vaccine acceptance, confidence, and trust among medically underserved and vulnerable populations living in the rural south.
Hypotheses:
H1a. It is hypothesized that top reasons for vaccine hesitancy may include access to care issues (such as transportation, long wait times, no available appointments, not sure where to go, no internet, and language barriers), safety and efficacy concerns, distrust in government and health organizations, as well as lack of information and/or misinformation.
H1b. It is hypothesized that structural barriers to vaccination may include geographic barriers, access to information, clinic/outlet location or trusted points of access, internet access, immigrant status, language, transportation, among others.
H1c. It is hypothesized that vaccine messaging received from trusted individuals in the communities (i.e., faith-based leaders, community health workers, and community leaders) will have impacted confidence and uptake more so than other vaccine messaging efforts.
H2. It is hypothesized that the vaccine messaging from trusted individuals will be mixed with some messaging based on science and some based on anecdotal evidence. It is not well-known what messages are being delivered around vaccination from trusted individuals who serve our priority population and thus, we can only hypothesize that the messaging will vary.
H3. It is hypothesized that the most effective strategies to boost vaccine confidence and uptake for vaccine hesitant, medically underserved, and vulnerable populations living in the rural south will include culturally tailored messaging from engagement with trusted individuals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vaccine hesitant
We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC)
Qualitative interviews/focus groups
We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
Trusted community leaders
We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve medical underserved individuals living in rural eastern North Carolina (ENC) .
Qualitative interviews/focus groups
We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qualitative interviews/focus groups
We will conduct quantitative (survey) and qualitative assessments (interviews/focus groups) with 40 vaccine hesitant, Black, Hispanic, and medical underserved individuals living in rural eastern North Carolina (ENC) and with 40 trusted individuals such as clergy/church leaders, community health workers, and community leaders who serve these populations.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
East Carolina University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Carolina University
Greenville, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22-0682
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.